» Articles » PMID: 37942486

Ion Channels in Lung Cancer: Biological and Clinical Relevance

Overview
Journal Front Pharmacol
Date 2023 Nov 9
PMID 37942486
Authors
Affiliations
Soon will be listed here.
Abstract

Despite improvements in treatment, lung cancer is still a major health problem worldwide. Among lung cancer subtypes, the most frequent is represented by adenocarcinoma (belonging to the Non-Small Cell Lung Cancer class) although the most challenging and harder to treat is represented by Small Cell Lung Cancer, that occurs at lower frequency but has the worst prognosis. For these reasons, the standard of care for these patients is represented by a combination of surgery, radiation therapy and chemotherapy. In this view, searching for novel biomarkers that might help both in diagnosis and therapy is mandatory. In the last 30 years it was demonstrated that different families of ion channels are overexpressed in both lung cancer cell lines and primary tumours. The altered ion channel profile may be advantageous for diagnostic and therapeutic purposes since most of them are localised on the plasma membrane thus their detection is quite easy, as well as their block with specific drugs and antibodies. This review focuses on ion channels (Potassium, Sodium, Calcium, Chloride, Anion and Nicotinic Acetylcholine receptors) in lung cancer (both Non-Small Cell Lung Cancer and Small Cell Lung Cancer) and recapitulate the up-to-date knowledge about their role and clinical relevance for a potential use in the clinical setting, for lung cancer diagnosis and therapy.

Citing Articles

A comprehensive investigation of PRMT5 in the prognosis and ion channel features of lung cancer.

Wang Y, Chu D, Li H, Fan J, Zhu X, Ma Y Front Oncol. 2024; 14:1478672.

PMID: 39678513 PMC: 11638061. DOI: 10.3389/fonc.2024.1478672.


Phytochemical Modulation of Ion Channels in Oncologic Symptomatology and Treatment.

Rao R, Mohammed C, Alschuler L, Pomeranz Krummel D, Sengupta S Cancers (Basel). 2024; 16(9).

PMID: 38730738 PMC: 11083444. DOI: 10.3390/cancers16091786.

References
1.
Jang S, Choi S, Ryu P, Lee S . Anti-proliferative effect of Kv1.3 blockers in A549 human lung adenocarcinoma in vitro and in vivo. Eur J Pharmacol. 2010; 651(1-3):26-32. DOI: 10.1016/j.ejphar.2010.10.066. View

2.
Kouokam J, Meaza I, Wise Sr J . Inflammatory effects of hexavalent chromium in the lung: A comprehensive review. Toxicol Appl Pharmacol. 2022; 455:116265. PMC: 10024459. DOI: 10.1016/j.taap.2022.116265. View

3.
DU G, Li J, Liu W, Liu Y, Zhao B, Li H . The combination of TRPM8 and TRPA1 expression causes an invasive phenotype in lung cancer. Tumour Biol. 2013; 35(2):1251-61. DOI: 10.1007/s13277-013-1167-3. View

4.
He W, Li H, Min X, Liu J, Hu B, Hou S . Activation of volume-sensitive Cl(-) channel is involved in carboplatin-induced apoptosis in human lung adenocarcinoma cells. Cancer Biol Ther. 2010; 9(11):885-91. DOI: 10.4161/cbt.9.11.11666. View

5.
Ko E, Kim Y, Lee D, Choi J, Kim S, Seo Y . Expression of potassium channel genes predicts clinical outcome in lung cancer. Korean J Physiol Pharmacol. 2019; 23(6):529-537. PMC: 6819903. DOI: 10.4196/kjpp.2019.23.6.529. View